Wide Ranks

EVAX

Evaxion Biotech A/S

1.57

Top Statistics
Market Cap 9 M Forward PE -14.27 Revenue Growth 0.00 %
Current Ratio 0.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.53 Enterprise / Revenue 24.94 Price To Sales Trailing12 Months 2.80
Profitability
Profit Margins 0.00 % Operating Margins -57.38 %
Balance Sheet
Total Cash 4 M Total Cash Per Share 0.0830 Total Debt
Total Debt To Equity Current Ratio 0.00 Book Value Per Share 0.0130
All Measures
Short Ratio 127.00 % Message Board Id finmb_319014926 Shares Short Prior Month 67408
City Horsholm Uuid 10e58503-7bd5-32f9-974e-d651a4f9f505 Previous Close 1.59
First Trade Date Epoch Utc 1 B Book Value 0.0130 Beta -0.2290
Volume 55723 Price To Book 120.77 Last Split Date 1 B
Fifty Two Week Low 1.28 Total Cash Per Share 0.0830 Total Revenue 3 M
Shares Short Previous Month Date 1 B Target Median Price 10.62 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -57.38 % Target Mean Price 11.56
Net Income To Common -11461000 Short Percent Of Float 0.0084 Implied Shares Outstanding 37 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 52070
Average Volume10days 52070 Total Cash 4 M Next Fiscal Year End 1 B
Revenue Per Share 0.7130 Held Percent Insiders 0.2525 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.59
Target Low Price 7.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.50
Open 1.65 Dividend Yield 0.00 % Return On Assets -0.6945
Time Zone Short Name EST Trailing Eps -2.80 Day Low 1.55
Address1 Dr. Neergaards Vej Shares Outstanding 5 M Price Hint 4
Target High Price 18.00 Website https://www.evaxion-biotech.com 52 Week Change -0.8035
Average Volume 54334 Forward Eps -1.26 Recommendation Key none
Compensation As Of Epoch Date 1 B Last Split Factor 1:10 Regular Market Day High 1.83
Is_sp_500 False Profit Margins 0.00 % Fifty Two Week High 13.61
Day High 1.83 Shares Short 36019 Regular Market Open 1.65
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 24.94
Revenue Growth 0.00 % Shares Percent Shares Out 0.0061 Currency USD
Time Zone Full Name America/New_York Market Cap 9 M Is_nasdaq_100 False
Zip 2970 Quote Type EQUITY Industry Biotechnology
Long Name Evaxion Biotech A/S Regular Market Day Low 1.55 Held Percent Institutions 0.0990
Current Price 1.57 Address2 5th Floor Enterprise To Ebitda -5.53
Financial Currency USD Current Ratio 0.00 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country Denmark
Float Shares 35 M Two Hundred Day Average 3.14 Enterprise Value 82 M
Price To Sales Trailing12 Months 2.80 Forward PE -14.27 Regular Market Volume 55723
Ebitda -14873750 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.

The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.

Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S.

aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N.

gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus.

Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.